Please note: The information displayed on this page might be outdated.
MorphoSys AG: MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 330 employees. More information at https://www.morphosys.com.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III, Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune, Cardiovascular, Central Nervous System, Infectious Disease, Oncology
Finance
Profitable, Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Antibodies
Website:
Address:
Germany

Company Participants at Class of 2018 Biotech IPO Investor Day

  • Simon E. Moroney, CEO

Top 10 Holders of MorphoSys AG

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Baillie Gifford & Co. 6.23 2,048,414 54.65 Stakes 3/16/20
T. Rowe Price International Ltd. 5.30 1,693,743 45.19 Stakes 10/23/20
Artisan Partners LP 3.15 1,005,929 26.84 Stakes 10/13/20
Invesco Advisers, Inc. 3.11 991,524 26.45 Stakes 10/28/20
Norges Bank Investment Management 3.03 966,702 25.79 Stakes 6/23/20
Fidelity Management & Research Co. LLC 2.92 961,696 25.66 Stakes 4/30/20
The Vanguard Group, Inc. 2.80 895,031 23.88 Funds 10/31/20
Flossbach von Storch AG 1.78 586,866 15.66 Funds 3/31/20
Capital Research & Management Co. (World Investors) 1.60 510,875 13.63 Funds 9/30/20
Credit Suisse Asset Management (Schweiz) AG 1.19 380,678 10.16 Funds 10/30/20

Top 10 Holders of MorphoSys AG Sponsored ADR

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
TimesSquare Capital Management LLC 1.41 1,802,619 48.09 13F 9/30/20
Massachusetts Financial Services Co. 0.43 547,733 14.61 13F 9/30/20
Candriam Luxembourg SCA 0.24 303,682 8.10 13F 9/30/20
Millennium Management LLC 0.21 269,087 7.18 13F 9/30/20
Morgan Stanley Capital Services LLC 0.18 230,551 6.15 13F 9/30/20
ALPS Advisors, Inc. (Subfiler) 0.13 169,887 4.53 13F 9/30/20
Citadel LP 0.08 105,691 2.82 13F 9/30/20
Candriam Belgium SA 0.07 94,000 2.51 Funds 4/30/20
Tekla Capital Management LLC 0.06 81,867 2.18 13F 9/30/20
AJO LP 0.05 63,500 1.69 Funds 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.